Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4297-4301

  Des Guetz, Gaëtan ^a   Lecaille, C ^c   Mariani, P ^d   Bennamoun, M ^e   Uzzan, B ^a   Nicolas, P ^a   Boisseau, A ^c   Sastre, X ^d   Cucherousset, J ^e   Lagorce, C ^a   Schischmanoff, P O ^a,b   Morere, J F ^a  

^a AVICENNE HOSPITAL   (France)

^b INSERM   (France)

^c Polyclinique Bordeaux Nord ^*  (France)

^d INSTITUT CURIE   (France)

^e Raincy Montfermeil Hospital   (France)

Author keywords

Adjuvant treatment; Cancer; Chemotherapy; Colorectal cancer treatment; FOLFOX; Microsatellite instability; Prognostic factor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PERITONEUM METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 78650249084     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW: Colorectal cancer. Lancet 365: 153-165, 2005.
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A and the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer I: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004.
3. Hermanek PS: L.H. Prognostic factors in colorectal cancer In: Prognostic Factors in Cancer. International Union Against Cancer. Springer, pp. 64-79, 1995.
4. Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou J-F, Duval A and Hamelin R: Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 24: 241-251, 2006.
5. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH and Kim YS: BRAF Mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10: 191-195, 2004.
6. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, Westra J, Frebourg T, EspÃn E, Armengol M, Hamelin R, Yamamoto H, Hofstra RMW, Seruca R, Lindblom A, Peltomäki P, Thibodeau SN, Aaltonen LA and Schwartz S: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genetics 41: 664-668, 2004.
7. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750, 2000.
8. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA and Joensuu H: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119: 921-928, 2000.
9. Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-18, 2005.
10. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
11. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C and for the Gastrointestinal Oncology Group of the Spanish Gastroenterological A: Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55: 848-855, 2006.
12. Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A and Gallinger S: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU-based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol (Meeting Abstracts) 26: 4008, 2008.
13. Benson AB, Catalan P, Meropol NJ, Giantonio BJ, Sigurdson ER, Martenson JA, Whitehead RP, Sinicrope F, Mayer RJ and O'Dwyer PJ: ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs. oxaliplatin, FU/LV (FOLFOX) vs. FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre- or postoperative radiation (RT)/FU. J Clin Oncol (Meeting Abstracts) 24: 3526, 2006.
14. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS and Redston M: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol 27: 1814-1821, 2009.
15. Tejpar S, Bosman F, Delorenzi M, Fiocca R, Yan P, Klingbiel D, Dietrich D, Van Cutsem E, Labianca R and Roth A: Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol (Meeting Abstracts) 27: 4001, 2009.
16. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090, 1996. (Pubitemid 26199755)
17. Tajima A, Hess MT, Cabrera BL, Kolodner RD and Carethers JM: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127: 1678-1684, 2004.
18. Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M and Chauffert B: Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmacol 49: 445-452, 2002.
19. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996. (Pubitemid 26374423)
20. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A and Praz F: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated with 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 21(4): 772-780, 2010. doi:10.1093/annoc/mdp383.
21. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK and Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 659-667, 2010.
22. Roth AD, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E and Bosman F: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol (Meeting Abstracts) 27: 4002, 2009.
23. Muller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll SH, Porschen R, Schmiegel W and Graeven U: Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 23: 1033-1039, 2008.
24. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E and Bosman F: Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol 28: 466-474, 2010.